IN2015DN02233A - - Google Patents

Info

Publication number
IN2015DN02233A
IN2015DN02233A IN2233DEN2015A IN2015DN02233A IN 2015DN02233 A IN2015DN02233 A IN 2015DN02233A IN 2233DEN2015 A IN2233DEN2015 A IN 2233DEN2015A IN 2015DN02233 A IN2015DN02233 A IN 2015DN02233A
Authority
IN
India
Prior art keywords
dendrimer
macromolecule
eye
salt
generations
Prior art date
Application number
Inventor
Jacinth Kincaid; Fairley
Colin Paul; Barrett
Jeremy Robert Arthur; Paull
Original Assignee
Starpharma Pty Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Starpharma Pty Ltd filed Critical Starpharma Pty Ltd
Publication of IN2015DN02233A publication Critical patent/IN2015DN02233A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/74—Synthetic polymeric materials
    • A61K31/795—Polymers containing sulfur
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Ophthalmology & Optometry (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Virology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

A microbial infection in an eye of a subject is treated or prevented by topically administering to the eye an effective amount of a macromolecule or a pharmaceutically acceptable salt thereof that includes a dendrimer of 1 to 8 generations with one or more sulfonic acid - or sulfonate -containing moieties attached to one or more surface groups of the outermost generation of the dendrimer. Compositions containing the macromolecule or salt are useful in these methods.
IN2233DEN2015 2012-09-13 2013-09-13 IN2015DN02233A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261700714P 2012-09-13 2012-09-13
PCT/US2013/059810 WO2014043576A1 (en) 2012-09-13 2013-09-13 Method of treatment or prophylaxis of infections of the eye

Publications (1)

Publication Number Publication Date
IN2015DN02233A true IN2015DN02233A (en) 2015-08-21

Family

ID=50278734

Family Applications (1)

Application Number Title Priority Date Filing Date
IN2233DEN2015 IN2015DN02233A (en) 2012-09-13 2013-09-13

Country Status (10)

Country Link
US (2) US10149885B2 (en)
EP (1) EP2895161B1 (en)
JP (2) JP6419701B2 (en)
CN (2) CN105007910B (en)
CA (1) CA2884897C (en)
DK (1) DK2895161T3 (en)
ES (1) ES2633778T3 (en)
HK (1) HK1212619A1 (en)
IN (1) IN2015DN02233A (en)
WO (1) WO2014043576A1 (en)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8974825B2 (en) * 2007-07-06 2015-03-10 Lupin Limited Pharmaceutical compositions for gastrointestinal drug delivery
RU2667118C1 (en) * 2017-11-15 2018-09-14 Федеральное государственное бюджетное научное учреждение "Прикаспийский зональный научно-исследовательский ветеринарный институт" Ointment type panpharmacon for complex treatment of animal eye diseases and method of producing thereof
CN110664757B (en) * 2018-11-19 2022-08-02 成都瑞沐生物医药科技有限公司 Nanocrystalline eye drop, preparation method and application thereof

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AUPM623994A0 (en) * 1994-06-15 1994-07-07 Biomolecular Research Institute Limited Antiviral dendrimers
EP1096934B1 (en) 1998-07-14 2005-09-21 Pharmacia & Upjohn Company LLC Oxazolidinones to treat eye infections
AUPP584298A0 (en) 1998-09-14 1998-10-08 Starpharma Limited Antimicrobial and antiparasitic agents
AUPR412801A0 (en) * 2001-03-30 2001-05-03 Starpharma Limited Agent for the prevention and treatment of sexually transmitted disease s - I
WO2005007223A2 (en) * 2003-07-16 2005-01-27 Sasha John Programmable medical drug delivery systems and methods for delivery of multiple fluids and concentrations
PL1755616T3 (en) * 2004-04-08 2014-10-31 Eye Co Pty Ltd Treatment of exudative retinopathy with mineralcorticoids
MX2008005048A (en) 2005-10-18 2008-11-18 Starpharma Pty Ltd Microbicidal dendrimer composition delivery system.
AU2006308511B2 (en) * 2005-10-25 2013-06-13 Starpharma Pty Limited Macromolecular compounds having controlled stoichiometry
AU2007266260B2 (en) * 2006-05-31 2012-07-19 Medihoney Pty Ltd Medicinal compositions containing honey
CA2701291A1 (en) 2007-10-05 2009-04-09 Wayne State University Dendrimers for sustained release of compounds
WO2010096558A1 (en) * 2009-02-18 2010-08-26 Eyeon Particle Sciences Llc Bi-functional co-polymer use for ophthalmic and other topical and local applications
BR112012000381A2 (en) * 2009-07-07 2016-03-29 Adenovir Pharma Ab novel antiviral compounds useful for treating or preventing epidemic keratoconjunctivitis
RU2632110C2 (en) 2011-05-16 2017-10-02 Старфарма Пти Лтд Method for bacterial vaginosis treatment or prevention

Also Published As

Publication number Publication date
US11219691B2 (en) 2022-01-11
WO2014043576A1 (en) 2014-03-20
CN108452316A (en) 2018-08-28
US20150238557A1 (en) 2015-08-27
CA2884897C (en) 2021-07-27
JP2019001827A (en) 2019-01-10
CN105007910B (en) 2019-03-19
JP2015528509A (en) 2015-09-28
EP2895161A1 (en) 2015-07-22
EP2895161A4 (en) 2016-03-23
EP2895161B1 (en) 2017-05-03
CN105007910A (en) 2015-10-28
HK1212619A1 (en) 2016-06-17
US20190070249A1 (en) 2019-03-07
JP6419701B2 (en) 2018-11-07
US10149885B2 (en) 2018-12-11
JP6766114B2 (en) 2020-10-07
CN108452316B (en) 2022-04-15
DK2895161T3 (en) 2017-08-21
CA2884897A1 (en) 2014-03-20
ES2633778T3 (en) 2017-09-25

Similar Documents

Publication Publication Date Title
MX2020000404A (en) Syk inhibitors.
NZ607600A (en) Compositions for the treatment of diseases
MX349159B (en) Deuterated derivatives of ivacaftor.
NZ715747A (en) Syk inhibitors
CA2900335C (en) Synthetic analogs of epipolythiodioxopiperazines and uses thereof
MY183582A (en) Deuterated cftr potentiators
EA201890641A3 (en) SGC STIMULATORS
PH12015501576A1 (en) Substituted pyrrolopyrimidine compounds, compositions thereof, and methods of treatment therewith
MY161233A (en) Bis (fluoroalkyl)-1, 4-benzodiazepinone compounds
IN2014DN05986A (en)
MA33939B1 (en) 5-alkynyl-PYRIMIDINE
EA201391486A1 (en) METHODS AND COMPOSITIONS FOR THE TREATMENT OF PARKINSON'S DISEASE
NZ628294A (en) Compositions and methods of use of phorbol esters for the treatment of stroke
WO2015023976A3 (en) Selective grp94 inhibitors and uses thereof
EA201691044A1 (en) NEW OCTAGIDRO-CYCLOBUT [1,2-C; 3,4-C '] DIPIRROL-2-IL
MX2016005760A (en) Gsk-3 inhibitors.
EA201590183A1 (en) AZAINDOL DERIVATIVES PERFORMING AS PI3K INHIBITORS
EA201591628A1 (en) DEUTERED PALBOCYCLIB
CO7160080A2 (en) Lipid compositions of racecadot
MX2016003238A (en) Cationic antiseptic compositions.
BR112016029012A2 (en) method of treating non-small cell lung cancer and / or small cell lung cancer using thienotriazolodiazepine compounds
MX2016004963A (en) Salt and crystal forms of plk-4 inhibitor.
IN2015DN02233A (en)
EA201391586A1 (en) 17α-HYDROXYLASE / C-LIAZ INHIBITORS
EA201390757A1 (en) PETROXAZEPINS AS PI3K / mTOR INHIBITORS AND METHODS FOR THEIR USE AND MANUFACTURE